Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
